Targeting IL13R{alpha}2 in melanoma with a bispecific T-cell engager: expression profiling and preclinical evaluation
Background
Melanoma is a highly aggressive skin cancer, especially in advanced stages. While current treatments such as targeted therapies and immunotherapies have made significant progress, challenges like drug resistance and limited effectiveness in…